1-20 of 27
George Wilding
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement

Free
Chad Tang, Steven I. Sherman, Mellanie Price, Jun Weng, Suzanne E. Davis, David S. Hong, James C. Yao, Aman Buzdar, George Wilding, J. Jack Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (6): 1414–1421.
https://doi.org/10.1158/1078-0432.CCR-16-2439
Published: 14 March 2017
View articletitled, Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement
Open the PDF for Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement in another window
Includes: Supplementary data
Journal Articles

Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805

Free
Naomi B. Haas, Judith Manola, Bonnie Ky, Keith T. Flaherty, Robert G. Uzzo, Christopher J. Kane, Michael Jewett, Lori Wood, Christopher G. Wood, Michael B. Atkins, Janice J. Dutcher, George Wilding, Robert S. DiPaola
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (18): 4048–4054.
https://doi.org/10.1158/1078-0432.CCR-15-0215
Published: 14 September 2015
View articletitled, Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805
Open the PDF for Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805 in another window
Includes: Supplementary data
Journal Articles

Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer

Free
Douglas G. McNeel, Jordan T. Becker, Jens C. Eickhoff, Laura E. Johnson, Eric Bradley, Isabel Pohlkamp, Mary Jane Staab, Glenn Liu, George Wilding, Brian M. Olson
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (14): 3692–3704.
https://doi.org/10.1158/1078-0432.CCR-14-0169
Published: 14 July 2014
View articletitled, Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer
Open the PDF for Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate

Free
Glenn Liu, Robert Jeraj, Matt Vanderhoek, Scott Perlman, Jill Kolesar, Michael Harrison, Urban Simoncic, Jens Eickhoff, Lakeesha Carmichael, Bo Chao, Rebecca Marnocha, Percy Ivy, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (24): 7634–7644.
https://doi.org/10.1158/1078-0432.CCR-11-1677
Published: 18 December 2011
View articletitled, Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate
Open the PDF for Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate in another window
Journal Articles

Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer

Free
Dana Rathkopf, Glenn Liu, Michael A. Carducci, Mario A. Eisenberger, Aseem Anand, Michael J. Morris, Susan F. Slovin, Yasutsuna Sasaki, Shunji Takahashi, Seiichiro Ozono, Nga Kit Eliza Fung, Shinta Cheng, Jinping Gan, Marco Gottardis, Mary T. Obermeier, Jyotsna Reddy, Steven Zhang, Blisse J. Vakkalagadda, Leila Alland, George Wilding, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 880–887.
https://doi.org/10.1158/1078-0432.CCR-10-2955
Published: 15 February 2011
View articletitled, Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
Open the PDF for Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer in another window
Journal Articles

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

Free
Evan Y. Yu, George Wilding, Edwin Posadas, Mitchell Gross, Stephane Culine, Christophe Massard, Michael J. Morris, Gary Hudes, Fabio Calabrò, Shinta Cheng, Géralyn C. Trudel, Prashni Paliwal, Cora N. Sternberg
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7421–7428.
https://doi.org/10.1158/1078-0432.CCR-09-1691
Published: 30 November 2009
View articletitled, Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

Free
Howard A. Burris, III, Charles W. Taylor, Suzanne F. Jones, Kevin M. Koch, Melissa J. Versola, Niki Arya, Ronald A. Fleming, Deborah A. Smith, Lini Pandite, Neil Spector, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (21): 6702–6708.
https://doi.org/10.1158/1078-0432.CCR-09-0369
Published: 02 November 2009
View articletitled, A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies in another window
Journal Articles

An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer

Free
Glenn Liu, W. Kevin Kelly, George Wilding, Lance Leopold, Kimberli Brill, Bradley Somer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (9): 3172–3176.
https://doi.org/10.1158/1078-0432.CCR-08-2985
Published: 30 April 2009
View articletitled, An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
Open the PDF for An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer in another window
Journal Articles

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies

Free
Amye J. Tevaarwerk, Kyle D. Holen, Dona B. Alberti, Carolyn Sidor, Jamie Arnott, Check Quon, George Wilding, Glenn Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1460–1465.
https://doi.org/10.1158/1078-0432.CCR-08-1599
Published: 19 February 2009
View articletitled, Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies
Open the PDF for Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies in another window
Journal Articles

Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

Free
Alejandro D. Ricart, Anthony W. Tolcher, Glenn Liu, Kyle Holen, Garry Schwartz, Mark Albertini, Geoffrey Weiss, Salim Yazji, Chee Ng, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7924–7929.
https://doi.org/10.1158/1078-0432.CCR-08-0378
Published: 01 December 2008
View articletitled, Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study
Open the PDF for Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study in another window
Journal Articles

A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors

Free
Glenn Liu, Jill Kolesar, Douglas G. McNeel, Catherine Leith, Kathy Schell, Jens Eickhoff, Fred Lee, Anne Traynor, Rebecca Marnocha, Dona Alberti, James Zwiebel, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2732–2739.
https://doi.org/10.1158/1078-0432.CCR-07-1490
Published: 01 May 2008
View articletitled, A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors in another window
Journal Articles

Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer

Free
Steven Attia, Jens Eickhoff, George Wilding, Douglas McNeel, Jules Blank, Harish Ahuja, Alcee Jumonville, Michael Eastman, Daniel Shevrin, Michael Glode, Dona Alberti, Mary Jane Staab, Dottie Horvath, Jane Straus, Rebecca Marnocha, Glenn Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (8): 2437–2443.
https://doi.org/10.1158/1078-0432.CCR-07-4274
Published: 15 April 2008
View articletitled, Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer
Open the PDF for Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer in another window
Journal Articles

Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors

Free
Howard H. Bailey, Dona B. Alberti, James P. Thomas, Daniel L. Mulkerin, Kimberly A. Binger, Marco M. Gottardis, Robert E. Martell, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3623–3629.
https://doi.org/10.1158/1078-0432.CCR-07-0158
Published: 15 June 2007
View articletitled, Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors
Open the PDF for Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group

Free
Robert Gray, Judith Manola, Scott Saxman, John Wright, Jan Dutcher, Michael Atkins, Michael Carducci, William See, Christopher Sweeney, Glenn Liu, Mark Stein, Robert Dreicer, George Wilding, Robert S. DiPaola
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 1966–1969.
https://doi.org/10.1158/1078-0432.CCR-05-1136
Published: 11 April 2006
View articletitled, Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group
Open the PDF for Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group in another window
Journal Articles

Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

Free
Douglas G. McNeel, Jens Eickhoff, Fred T. Lee, David M. King, Dona Alberti, James P. Thomas, Andreas Friedl, Jill Kolesar, Rebecca Marnocha, Jennifer Volkman, Jianliang Zhang, Luz Hammershaimb, James A. Zwiebel, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7851–7860.
https://doi.org/10.1158/1078-0432.CCR-05-0262
Published: 08 November 2005
View articletitled, Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion
Open the PDF for Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion in another window
Journal Articles

A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer

Free
Christopher Sweeney, Glenn Liu, Constantin Yiannoutsos, Jill Kolesar, Dorothea Horvath, Mary Jane Staab, Karen Fife, Victoria Armstrong, Anthony Treston, Carolyn Sidor, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6625–6633.
https://doi.org/10.1158/1078-0432.CCR-05-0440
Published: 15 September 2005
View articletitled, A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer
Open the PDF for A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer in another window
Journal Articles

A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer

Free
Grace K. Dy, James P. Thomas, George Wilding, Laura Bruzek, Sumithra Mandrekar, Charles Erlichman, Dona Alberti, Kim Binger, Henry C. Pitot, Steven R. Alberts, Lorelei J. Hanson, Rebecca Marnocha, Kendra Tutsch, Scott H. Kaufmann, Alex A. Adjei
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3410–3416.
https://doi.org/10.1158/1078-0432.CCR-04-2068
Published: 02 May 2005
View articletitled, A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer
Open the PDF for A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer in another window
Journal Articles

A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer

Free
Lynn Van Ummersen, Kim Binger, Jennifer Volkman, Rebecca Marnocha, Kendra Tutsch, Jill Kolesar, Rhoda Arzoomanian, Dona Alberti, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (22): 7450–7456.
https://doi.org/10.1158/1078-0432.CCR-03-0406
Published: 29 November 2004
View articletitled, A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer
Open the PDF for A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer in another window
Journal Articles

Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor

Free
Kenneth R. Hande, Mary Collier, Linda Paradiso, Jill Stuart-Smith, Mary Dixon, Neil Clendeninn, Geoff Yeun, Donna Alberti, Kim Binger, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (3): 909–915.
https://doi.org/10.1158/1078-0432.CCR-0981-3
Published: 10 February 2004
View articletitled, Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor
Open the PDF for Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor in another window
Journal Articles

A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer

Free
Glenn Liu, David R. Gandara, Primo N. Lara, Jr., Derek Raghavan, James H. Doroshow, Przemyslaw Twardowski, Philip Kantoff, William Oh, KyungMann Kim, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (3): 924–928.
https://doi.org/10.1158/1078-0432.CCR-03-0050
Published: 10 February 2004
View articletitled, A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer
Open the PDF for A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer in another window